Lake Street Sticks to Their Buy Rating for Achieve Life Sciences (ACHV)

Lake Street analyst Thomas Flaten reiterated a Buy rating on Achieve Life Sciences today and set a price target of $11.00. The company’s shares closed yesterday at $2.92.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Flaten is a 2-star analyst with an average return of 0.8% and a 43.75% success rate. Flaten covers the Healthcare sector, focusing on stocks such as Harrow Health, Insight Molecular Diagnostics, and Aquestive Therapeutics.

Currently, the analyst consensus on Achieve Life Sciences is a Strong Buy with an average price target of $14.60, a 400.00% upside from current levels. In a report released on August 21, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $12.00 price target.

Based on Achieve Life Sciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $12.72 million. In comparison, last year the company had a GAAP net loss of $8.46 million